We use cookies in order to analyze traffic of this website. Your further use of this website will be considered consent. For more information visit our Cookie Policy.

Clinical Advisory Board

Clinical expertise and patient centricity promote safety and appropriate study design. Recognized leaders in neurodegenerative diseases support the Company in strategic clinical development and provide regulatory advice.

Clinical Advisory Board
  • Andreas U. Monsch, PHD

    Head, Memory Clinic, University Department of Geriatric Medicine FELIX PLATTER - Chairman

    Prof. Andreas U. Monsch studied clinical psychology, psychopathology, and neurophysiology at the University of Zurich (Switzerland) and received his doctorate in 1991. From 1991–1994, he worked at the University of California, San Diego (US), one of the best Alzheimer' disease research centers in the world at the time. From 1994–2002, he was head of research at the Memory Clinic of the Geriatric University Hospital in Basel (Switzerland). In 2001 he received his habilitation and was promoted to Professor of Psychology at the University of Basel in 2003. Since 2002, he has been in charge of one of the largest memory clinics in Switzerland, which has relocated to the Felix Platter Hospital in 2016, Basel, and which is now called University Department of Geriatric Medicine Felix Platter. Prof. Monsch's research and teaching focuses on "Early diagnosis of dementia" and "Rare causes of dementia". He has published over 170 papers and book chapters.

  • Pierre N. Tariot, MD

    Director of Banner Alzheimer’s Institute and Research Professor - Member

    Prof. Tariot is Board Certified in Internal Medicine and Psychiatry with added qualifications in geriatrics.  He was a Fellow at the National Institute of Mental Health (NIMH, US) Intramural Research Program, then served as a faculty member at the University of Rochester Medical Center and, since 2006, he has served as Director of the Banner Alzheimer’s Institute in Phoenix. He is also a Research Professor of Psychiatry at the University of Arizona College of Medicine. His work has focused on the care and study of people with, and at risk, of Alzheimer’s, with special emphasis on the design and implementation of clinical trials for prevention and treatment, development of biomarkers, and demonstration of effective dementia care. He has published over 350 papers on these topics including articles regarding studies that have led to FDA approval of new medications. He serves as co-director of the Alzheimer’s Prevention Initiative (API). His research affiliations include the National Institute on Aging (NIA), the NIMH, and the Alzheimer’s Association.

  • Murat Emre, MD

    Professor of Practice and Expert in Neurodegenerative Diseases - Member

    Prof. Murat Emre was born in 1956, in Eregli, Turkey. After studying medicine at the Istanbul Faculty of Medicine, which he graduated from in 1980, he was trained in neuroscience and clinical neurology at the University of Zürich 1981–1985. He then worked in the fields of neurorehabilitation and clinical research in Switzerland until 1996. During this time, he had two sabbaticals: he was trained in movement disorders with Prof. David Marsden at the Queen Square National Hospital for Nervous Diseases, London (UK) and in behavioral neurology with Prof. Marsel Mesulam at the Beth Israel Hospital and Harvard Medical School (US). In 1996 he was assigned as Professor of Neurology at the İstanbul Faculty of Medicine (Turkey) where he started the Behavioral Neurology and Movement Disorders Unit, which he chaired until 2011. He acted as Chairman of the Neurology Department in 2002–2003. In 2011 he retired from his position as full professor and was assigned as Adjunct Professor for Research. He was founding President of the Brain Research Society, the Alzheimer Society of Turkey and the Alzheimer Foundation and a past president of the Parkinson Society of Turkey. His areas of interest include movement disorders, in particular Parkinson’s disease and related disorders, especially cognitive aspects of the disease, as well as Alzheimer’s disease and related dementias.

  • Juan Fortea, MD, PHD

    Director of the Alzheimer Down Unit and Leader of the Down Alzheimer Barcelona Imaging Initiative - Member

    Dr. Fortea is a behavioral neurologist and a dementia expert. He combines his research and clinical activities at the Hospital of Sant Pau in Barcelona (Spain) and the Catalan Foundation for Down Syndrome, where he is the director of the Alzheimer Down Unit. He leads the Down Alzheimer Barcelona Neuroimaging Initiative (DABNI), the largest single center cohort with multimodal biomarker studies to study Alzheimer´s disease pathophysiology in Down syndrome. He has extensive experience in clinical practice and in medical research, with a focus on the early diagnosis of neurodegenerative diseases, Alzheimer’s disease and Down syndrome-related Alzheimer’s disease. His expertise is recognized internationally, as an active participant of the NIA-N Study section, National Institutes of Health (US), the International Scientific Committee of the Jerome Lejeune Foundation (France) as well as at the Clinical Research Committee from the Trisomy 21 Research Society and the Down Syndrome Professional Interest Area, Alzheimer’s Association (US). He is also the current Chair of the Behavioral Neurology and Dementia Study Group at the Spanish Neurological Society.

  • Reisa Sperling, MD

    Director of the Center for Alzheimer Research and Treatment and Professor in Neurology - Member

    Dr. Reisa Sperling is a neurologist focused on the detection and treatment of Alzheimer’s disease at the pre-symptomatic or “preclinical” stage. Dr. Sperling is a Professor in Neurology at Harvard Medical School (US), and Director of the Center for Alzheimer Research and Treatment at Brigham and Women’s Hospital and Massachusetts General Hospital. Dr. Sperling is the co-Principal Investigator of the Harvard Aging Brain Study, and the NIH funded Alzheimer Clinical Trial Consortium (ACTC). Dr. Sperling chaired the 2011 NIA-Alzheimer’s Association workgroup to develop guidelines for the study of “Preclinical Alzheimer’s disease”. She co-leads the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s disease (A4) Study and is launching two new AD prevention trials (A3-45) with the ACTC in 2020. Dr. Sperling received the 2011 Derek Denny-Brown Award, the 2015 American Academy of Neurology Potamkin Prize, and was named one of the 2017 Most Disruptive Women to Watch in Healthcare.

  • Lon S. Schneider, MD, MS

    Director of the USC State of California Alzheimer’s Disease Center - Member

    Dr. Schneider is Professor of Psychiatry, Neurology, and Gerontology at the Keck School of Medicine and Leonard Davis School of Gerontology of the University of Southern California (US). He directs the USC State of California Alzheimer’s Disease Center, the clinical core of the USC National Institute on Aging Alzheimer’s Disease Research Center, and the Geriatric Studies Center. He holds a Master’s degree in Biometry and Epidemiology and has expertise in clinical trials methods and drug development. His work involves treatment development with novel metabolic and neuroregenerative compounds, outcomes assessment, and approaches to modelling, clinical trials simulations, and, recently, in silico screening of medications for slowing Alzheimer’s disease. He is a Fellow of the American College of Neuropsychopharmacology, and Distinguished Life Fellow of the American Psychiatric Association.